Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 18, 2015; 7(5): 725-737
Published online Apr 18, 2015. doi: 10.4254/wjh.v7.i5.725
Published online Apr 18, 2015. doi: 10.4254/wjh.v7.i5.725
Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade
Heidi Barth, Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
Author contributions: Barth H designed and wrote the article for the work.
Conflict-of-interest: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Heidi Barth, Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, 3 rue Koeberlé, 67000 Strasbourg, France. heidi.barth@chru-strasbourg.fr
Telephone: +33-369-551548 Fax: +33-368-853750
Received: November 26, 2014
Peer-review started: November 29, 2014
First decision: December 12, 2014
Revised: December 22, 2014
Accepted: January 18, 2015
Article in press: January 20, 2015
Published online: April 18, 2015
Processing time: 144 Days and 14.3 Hours
Peer-review started: November 29, 2014
First decision: December 12, 2014
Revised: December 22, 2014
Accepted: January 18, 2015
Article in press: January 20, 2015
Published online: April 18, 2015
Processing time: 144 Days and 14.3 Hours
Core Tip
Core tip: Twenty-five years after the discovery of hepatitis C virus (HCV) as the major cause of non-A, non-B post-transfusion hepatitis, we have entered a new era in HCV treatment that indicates the prospect of eradication of this important human pathogen. In this article, we will discuss the promising opportunities ahead and key future challenges in the era of new hepatitis C treatments, i.e., barriers in identifying HCV infected individuals, access to new HCV drugs, emergence of drug resistance, and the current status of HCV vaccine development.